January 24, 2017 9:43 AM ET

Healthcare Providers and Services

Company Overview of Memorial Sloan Kettering Cancer Center

Company Overview

Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...

1275 York Avenue

67th-68th Streets

New York, NY 10065

United States

Founded in 1884

Phone:

212-639-2000

Fax:

212-717-3299

Key Executives for Memorial Sloan Kettering Cancer Center

Chief Executive Officer and President
Age: 63
Senior Vice President of Finance
Chief Operating Officer
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Compensation as of Fiscal Year 2016.

Memorial Sloan Kettering Cancer Center Key Developments

Avacta Group plc Announces the Research Collaboration with Memorial Sloan Kettering Cancer Center

Avacta Group Plc announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta's Affimer technology in novel CAR-T cell-based immunotherapy. CAR-T immunotherapy is a form of cancer treatment in which the patient's own immune system T cells are modified to give them greater potency with which to attack cancer cells. Treatments using these engineered immune cells have generated promising responses in patients with advanced cancers and CAR-T immunotherapy has become an intense area of research, clinical development and investment. As part of the collaboration Avacta will develop Affimer molecules that bind different regions of CD19, a surface protein specific to B-cells involved in lymphomas. Dr. Brentjens' team will construct CAR-T cells incorporating these Affimer molecules and test their anti-tumour function in vitro and in vivo animal efficacy models. Under the terms of the agreement the ownership of the results generated directly as part of this collaboration will be shared between Avacta and MSK.

Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd., Bay City Capital and Deerfield Management Announce the Establishment of a New Drug Discovery Company

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases. Bridge Medicines builds upon the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute, known as Tri-I TDI. Scientists at the Tri-I TDI, which launched in 2013, are working in the laboratory on approximately 50 early-stage drug discovery projects, spanning therapeutic areas including infectious disease, oncology, neuropsychiatry and rare diseases, with the hope that they might be translated into future treatments for patients. Research projects accepted into the Tri-I TDI will now be able to graduate to Bridge Medicines, where they will be given financial, operational and managerial support to move seamlessly from a validating, proof-of-concept study to an in-human clinical trial. Typically, investigators behind promising early-stage discoveries must search for a biopharmaceutical company to purchase or license their intellectual property, or find a funding opportunity to support additional research. This process can be time consuming and may shift investigators' focus away from science, slowing down and in some cases ending the development path.

Memorial Sloan Kettering Cancer Center Presents at The Cell & Gene Meeting on the Mesa, Oct-07-2016 04:20 PM

Memorial Sloan Kettering Cancer Center Presents at The Cell & Gene Meeting on the Mesa, Oct-07-2016 04:20 PM. Venue: La Jolla, CA 92037, United States. Speakers: Lorenz Studer, Director, Center for Stem Cell Biology.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1104 Welsh Road Operations LLC United States

Recent Private Companies Transactions

Type
Date
Target
Buyback
August 5, 2016
Juno Therapeutics, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Memorial Sloan Kettering Cancer Center, please visit www.mskcc.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.